PMID- 30608516
OWN - NLM
STAT- MEDLINE
DCOM- 20191224
LR  - 20200309
IS  - 1476-6256 (Electronic)
IS  - 0002-9262 (Print)
IS  - 0002-9262 (Linking)
VI  - 188
IP  - 4
DP  - 2019 Apr 1
TI  - Rethinking Antimicrobial Resistance Surveillance: A Role for Lot Quality 
      Assurance Sampling.
PG  - 734-742
LID - 10.1093/aje/kwy276 [doi]
AB  - Global surveillance of antimicrobial resistance (AMR) is a key component of the 
      68th World Health Assembly Global Action Plan on AMR. Laboratory-based 
      surveillance is inherently biased and lacks local relevance due to aggregation of 
      data. We assessed the feasibility, sensitivity, and affordability of a 
      population-based AMR survey using lot quality assurance sampling (LQAS), which 
      classifies a population as having a high or low prevalence of AMR based on a 
      priori defined criteria. Three studies were carried out in Medan and Bandung, 
      Indonesia, between April 2014 and June 2017. LQAS classifications for 15 
      antibiotics were compared with AMR estimates from a conventional population-based 
      survey, with an assessment of the cost of a single LQAS classification using 
      microcosting methodology, among patients suspected of urinary tract infection at 
      11 sites in Indonesia. The sensitivity of LQAS was above 98%. The approach 
      detected local variation in the prevalence of AMR across sites. Time to reach 
      LQAS results ranged from 47 to 138 days. The average cost of an LQAS 
      classification in a single facility was US$466. The findings indicate that 
      LQAS-based AMR survey is a feasible, sensitive, and affordable strategy for 
      population-based AMR surveys, providing essential data to inform local empirical 
      treatment guidelines and antimicrobial stewardship efforts.
CI  - (c) The Author(s) 2019. Published by Oxford University Press on behalf of the Johns 
      Hopkins Bloomberg School of Public Health.
FAU - Ginting, Franciscus
AU  - Ginting F
AD  - Department of Internal Medicine, Faculty of Medicine, University of Sumatera 
      Utara, H. Adam Malik Hospital, Medan, Indonesia.
FAU - Sugianli, Adhi Kristianto
AU  - Sugianli AK
AD  - Department of Clinical Pathology, Faculty of Medicine, Universitas Padjadjaran, 
      Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.
FAU - Bijl, Gidion
AU  - Bijl G
AD  - Amsterdam Institute for Global Health and Development, Amsterdam, the 
      Netherlands.
FAU - Saragih, Restuti Hidayani
AU  - Saragih RH
AD  - Department of Internal Medicine, Faculty of Medicine, University of Sumatera 
      Utara, H. Adam Malik Hospital, Medan, Indonesia.
FAU - Kusumawati, R Lia
AU  - Kusumawati RL
AD  - Department of Microbiology, Faculty of Medicine, University of Sumatera Utara, H. 
      Adam Malik Hospital, Medan, Indonesia.
FAU - Parwati, Ida
AU  - Parwati I
AD  - Department of Clinical Pathology, Faculty of Medicine, Universitas Padjadjaran, 
      Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.
FAU - de Jong, Menno D
AU  - de Jong MD
AD  - Department of Medical Microbiology, Amsterdam University Medical Centers, 
      Academic Medical Center, Amsterdam, the Netherlands.
FAU - Schultsz, Constance
AU  - Schultsz C
AD  - Amsterdam Institute for Global Health and Development, Amsterdam, the 
      Netherlands.
AD  - Department of Medical Microbiology, Amsterdam University Medical Centers, 
      Academic Medical Center, Amsterdam, the Netherlands.
AD  - Department of Global Health, Amsterdam University Medical Centers, Academic 
      Medical Center, Amsterdam, the Netherlands.
FAU - van Leth, Frank
AU  - van Leth F
AD  - Amsterdam Institute for Global Health and Development, Amsterdam, the 
      Netherlands.
AD  - Department of Global Health, Amsterdam University Medical Centers, Academic 
      Medical Center, Amsterdam, the Netherlands.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Epidemiol
JT  - American journal of epidemiology
JID - 7910653
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - *Drug Resistance, Bacterial
MH  - Feasibility Studies
MH  - Humans
MH  - Indonesia
MH  - Lot Quality Assurance Sampling/*methods
MH  - Population Surveillance/*methods
MH  - Prevalence
PMC - PMC6438814
OTO - NOTNLM
OT  - antimicrobial stewardship
OT  - drug resistance, microbial
OT  - lot quality assurance sampling
OT  - sentinel surveillance
OT  - urinary tract infections
EDAT- 2019/01/05 06:00
MHDA- 2019/12/25 06:00
PMCR- 2019/01/04
CRDT- 2019/01/05 06:00
PHST- 2018/07/09 00:00 [received]
PHST- 2018/12/16 00:00 [revised]
PHST- 2018/12/18 00:00 [accepted]
PHST- 2019/01/05 06:00 [pubmed]
PHST- 2019/12/25 06:00 [medline]
PHST- 2019/01/05 06:00 [entrez]
PHST- 2019/01/04 00:00 [pmc-release]
AID - 5273260 [pii]
AID - kwy276 [pii]
AID - 10.1093/aje/kwy276 [doi]
PST - ppublish
SO  - Am J Epidemiol. 2019 Apr 1;188(4):734-742. doi: 10.1093/aje/kwy276.